Clinical trialNCT01623232WithdrawnPhase 1/PHASE2Interventional

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly

SponsorUS Department of Veterans AffairsEnrollment0AgedInfluenza Vaccines

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1,2 randomized, double-blind, multi-center, clinical trial, in participants aged 65 years and older, evaluating the immunogenicity and safety of a water-in-oil emulsion adjuvant (MAS-1 adjuvant, Mercia Pharma, Inc, Scarsdale, NY) combined with each of the three reduced HA antigen dose levels of trivalent influenza virus vaccine compared with licensed, unadjuvanted, standard dose trivalent virus (TIV). Immunogenicity for each of the three viral strains (A/H1N1, A/H3N2, and B virus) in the concurrent influenza seasonal vaccine will be assessed.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Geoffrey J. Gorse, MD
St. Louis VA Medical Center John Cochran Division, St. Louis, MO
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Va Palo Alto Health Care System, Palo Alto, Ca
Palo Alto, California, United States
Iowa City Va Health Care System, Iowa City, Ia
Iowa City, Iowa, United States
Minneapolis Va Health Care System, Minneapolis, Mn
Minneapolis, Minnesota, United States
St. Louis Va Medical Center John Cochran Division, St. Louis, Mo
St Louis, Missouri, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MAS-1 adjuvant and influenza HA antigenStandard dose, inactivated trivalent influenza vaccine

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2012
Primary completion: 30 Nov 2013
Completion: 30 Jun 2014
Last update posted: 26 Sept 2012
Registered enrollment: 0
Registry id: NCT01623232

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.